Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sharper breast scans? new technique aims to reduce image flaws

NCT ID NCT03155386

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an improved version of angiomammography, a special breast X-ray that uses dye to highlight blood vessels. Researchers compared the new method to the standard SenoBright® technique in 100 women aged 40 to 70. Three radiologists reviewed the images to see which method had fewer artifacts and better quality. The goal was to see if the optimized approach could provide clearer images for diagnosing breast conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to clearer breast images with fewer artifacts, helping doctors make more accurate diagnoses.
What could go wrong
This is a small, completed study focused on image quality, not on patient outcomes. The new technique may not prove better in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

May 2017

Finished

Oct 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients for whom an angiomammographic examination is requested regardless of its indication

Ages

40 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient for whom angiomammography examination is requested regardless of its indication (assessment of extension, clarification of a lesion doubtful after mammography and mammary ultrasound, symptom mammary MRI in a patient with contraindication to MRI) 2. Patient aged 40 to 70 years 3. Informing the patient or his / her legal representative and signing the form of non-opposition. 4. Patient affiliated to a social security system. Exclusion Criteria: 1. Patient with breast prostheses 2. Patient with a genetic mutation (BRCA1, BRCA2, p57) 3. Contraindication to injection of iodinated contrast agent 4. Pregnant woman, likely to be pregnant or breastfeeding, 5. Persons deprived of their liberty or under guardianship, 6. Unable to undergo medical follow-up of the trial for reasons geographical, social or psychological.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Patients for whom an angiomammogram examination is requested whether its indication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gustave Roussy

    Villejuif, Val de Marne, 94805, France